Amicus Therapeutics, Inc. (FOLD)


-0.20 (-1.74%)
Symbol FOLD
Price $11.025
Beta 0.865
Volume Avg. 2.44M
Market Cap 3.233B
Shares () -
52 Week Range 9.7-14.1
1y Target Est -
DCF Unlevered FOLD DCF ->
DCF Levered FOLD LDCF ->
ROE -147.61% Strong Sell
ROA -22.72% Sell
Operating Margin -
Debt / Equity 340.96% Strong Buy
P/E -18.69 Strong Sell
P/B 24.47 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest FOLD news

Mr. Bradley L. Campbell M.B.A.
NASDAQ Global Market

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.